Imprimis Pharmaceuticals Inc., a specialty pharmaceutical company, has expanded the availability of its proprietary ophthalmic and urologic compounded formulations to physicians and patients in Texas.
"In order to take advantage of these opportunities, we have hired regional business directors in both ophthalmology and urology specifically to cover this market,” Imprimis CEO Mark L. Baum said. “We have already begun to reach out to dozens of ophthalmology practices that have expressed interest in implementing our Dropless Therapy in their practices. “
The expansion into Texas resulted from Imprimis’ recent acquisition of JT Pharmacy Inc., doing business as Central Allen Pharmacy, a compounding pharmacy located outside of Dallas.
“The acquisition of our third compounding pharmacy and licensure in Texas represents an important milestone for our company and for me personally because I was born and raised in Texas and have a special appreciation for its size and dynamism,” Baum said. “Texas has experienced tremendous growth over the past several years due to its attractive tax climate, diverse economy, low unemployment, highly skilled and educated work force, affordable housing and several large and growing cities such as Dallas, Austin, San Antonio and Houston. We are confident that our investment in Texas will blossom just like a field of beautiful bluebonnets."